Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
300 participants
INTERVENTIONAL
2026-01-01
2026-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sleep Supplement
Sleep Supplement
Sleep Supplement
Powdered sleep supplement
Usual Diet
Usual Diet
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sleep Supplement
Powdered sleep supplement
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
RU-SATED score ≤7. Willing and able to follow the study protocol. Willing to discontinue any other supplements (including nootropics, adaptogens, calming herbs), medications, herbal remedies, or over-the-counter sleep medications (e.g., zolpidem, diphenhydramine, Benadryl, ZzzQuil, Unisom, magnesium or melatonin products) used to assist with sleep during the study.
Agree to limit alcohol intake within approximately 4 hours of bedtime throughout participation.
Agree to limit caffeine intake to ≤400 mg/day (about 3-4 cups of coffee) and avoid ingestion of caffeine-containing products after 2:00 PM during the study period.
Generally healthy and not living with any uncontrolled chronic disease. Resides in the United States. Willing to discontinue any restricted products and adhere to all required study assessments.
Exclusion Criteria
Current use of sleep-tracking technology (e.g., wrist-worn trackers, rings, smartphone apps) that could influence sleep behavior or perception.
Women currently undergoing perimenopause or experiencing vasomotor symptoms (e.g., night sweats).
Use of hormone therapy (estrogen, progesterone, phytoestrogens) within the last 3 months.
Diagnosed psychiatric disorders including major depressive disorder with acute symptoms, bipolar disorder, generalized anxiety disorder with active symptoms, and PTSD with frequent nightmares.
Diagnosed neurodegenerative or chronic pain disorders, including Parkinson's disease, Alzheimer's disease, or uncontrolled fibromyalgia.
Regular prescribed stimulant use (e.g., amphetamines such as Adderall/Vyvanse; methylphenidate such as Ritalin/Concerta; modafinil/armodafinil).
Current use of CNS-activating antidepressants (bupropion, fluoxetine, venlafaxine, sertraline).
Current or recent use of cannabis or THC-containing products (recreational or medicinal marijuana, CBD with measurable THC, synthetic cannabinoids) within the past 30 days.
Employment in jobs disrupting nighttime sleep (e.g., night shift, rotating shift, excessive travel).
Current use of prescription sleep aids. Introduction of any new sleep-related supplements, medications, herbal remedies, or melatonin products during the study.
Use of any prescription or OTC products with sedative properties (e.g., melatonin, diphenhydramine, doxylamine, valerian, ZzzQuil, Advil PM) within 4 weeks prior to enrollment or habitual use ≥3 times per week prior to enrollment unless investigator-approved.
Allergy or sensitivity to any study product ingredients. Pregnant, breastfeeding, or trying to conceive during the study period. History of substance abuse. Heavy alcohol use (≥8 drinks/week for women or ≥15 drinks/week for men). Participation in another research study now or within the next 7 weeks. Any condition or behavior that, in the investigator's judgment, may interfere with study participation or data integrity.
22 Years
59 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Athletic Greens International
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Philip Sapp, PhD, MS
Role: PRINCIPAL_INVESTIGATOR
Athletic Greens - AG1
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alethios (Virtual Study Platform)
San Francisco, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Zeenia Framroze
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AGZ001
Identifier Type: -
Identifier Source: org_study_id